Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Continuous buccolingual masticatory dyskinesia in Parkinson's disease.

Meyniel C, Derkinderen P, Giumelli B, Damier P.

BMJ Case Rep. 2012 Sep 25;2012. pii: bcr0920080910. doi: 10.1136/bcr.09.2008.0910.

PMID:
23010135
2.

Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.

Jenner P.

Mov Disord. 2008;23 Suppl 3:S585-98. doi: 10.1002/mds.22022. Review.

PMID:
18781676
3.

[Pergolide: a useful agonist for the treatment of Parkinson disease].

Bonnet AM, Houeto JL.

Rev Neurol (Paris). 2002 Jul;158(6-7):744-5. French.

PMID:
12486908
4.

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.

Carpentier AF, Bonnet AM, Vidailhet M, Agid Y.

Neurology. 1996 Jun;46(6):1548-51.

PMID:
8649546
5.

Pergolide in the treatment of patients with early and advanced Parkinson's disease.

Bonuccelli U, Colzi A, Del Dotto P.

Clin Neuropharmacol. 2002 Jan-Feb;25(1):1-10. Review.

PMID:
11852289
6.

High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.

Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.

Parkinsonism Relat Disord. 2005 Sep;11(6):393-8.

PMID:
15993640
7.

Pergolide for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M.

Cochrane Database Syst Rev. 2000;(2):CD000235. Review.

PMID:
10796704
8.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group..

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
9.

The initial treatment of Parkinson's disease should begin with levodopa.

Weiner WJ.

Mov Disord. 1999 Sep;14(5):716-24. Review.

PMID:
10495031
10.

Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.

Crevits L, Versijpt J, Hanse M, De Ridder K.

Neuropsychobiology. 2000;42(4):202-6.

PMID:
11096336
11.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group..

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
12.

Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Nyholm D.

Clin Pharmacokinet. 2006;45(2):109-36. Review.

PMID:
16485914
13.

Therapeutic strategies to prevent motor complications in Parkinson's disease.

Kieburtz K.

J Neurol. 2008 Aug;255 Suppl 4:42-5. doi: 10.1007/s00415-008-4007-4. Review.

PMID:
18821085
15.

A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.

Kulisevsky J, López-Villegas D, García-Sánchez C, Barbanoj M, Gironell A, Pascual-Sedano B.

Clin Neuropharmacol. 1998 Nov-Dec;21(6):358-62.

PMID:
9844794
16.

The variability of levodopa response in Parkinson's disease: is sensitization reversible?

Jabre MG, Bejjani BP.

Mov Disord. 2008 Apr 30;23(6):924; author reply 925. doi: 10.1002/mds.21893. No abstract available.

PMID:
18163452
17.

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.

Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.

PMID:
23853029
18.
19.

Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.

Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20.

PMID:
26001615
20.

Supplemental Content

Support Center